House Bill 6003 Summary

• Establishes a working group by November 1, 2020 to determine whether Connecticut should create a program referring uninsured and insured diabetic patients to federally-qualified health centers for treatment, with recommendations due by May 1, 2021.

• Allows pharmacists to immediately prescribe and dispense up to a 30-day supply of insulin drugs, glucagon drugs, diabetes devices, and diabetic ketoacidosis devices to patients with less than a 7-day supply if risk of significant physical harm exists within 7 days.

• Requires individual and group health insurance policies to cover diabetes treatment including laboratory testing, insulin drugs, noninsulin drugs, and diabetes devices with cost caps of $25 per 30-day supply for insulin/glucagon drugs and $100 per 30-day supply for all diabetes devices.

• Mandates pharmacies report insulin drugs, glucagon drugs, diabetes devices, and diabetic ketoacidosis devices to the electronic prescription drug monitoring program at least daily, similar to controlled substance reporting requirements.

• Makes various updates to insurance regulations regarding high deductible health plans, coverage for needles/syringes, and adds telehealth provisions allowing out-of-state practitioners during COVID-19 emergency through March 15, 2021.